New data on two medicines for HAE to be presented at key European conference
Seven new abstracts of data on the HAE medicines berotralstat (Orladeyo) and navenibart are to be presented at the forthcoming European Academy of Allergy and Clinical Immunology from 12-15 June 2026.
The presentations will be:
- Real-world patient characterization, prior long-term prophylactic prescribing patterns, and treatment outcomes for adults on berotralstat with hereditary angioedema in Japan
- Berotralstat decreased HAE attacks treated with on-demand therapy or utilising professional care in paediatric patients aged 2 to <12 years: APeX-P results through 48 weeks
- Reductions in hereditary angioedema attacks among patients with C1 esterase inhibitor deficiency who switched from another long-term prophylaxis to berotralstat
- Hereditary angioedema attack rates among patients with normal C1 esterase inhibitor before and after switching from another long-term prophylaxis to berotralstat
- Reductions in healthcare resource utilization in adolescents with hereditary angioedema on berotralstat
- Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the alpha-star trial
- Hereditary angioedema attack frequency and severity according to individuals taking berotralstat for long-term prophylaxis
(Source: BioCryst)